Business
Nexstim Plc: Managers’ Transactions, Hannula
Nexstim Plc: Managers’ Transactions,
About this update from Nexstim Plc
Company Announcement, Helsinki, 15 May 2026 at 02:40 PM (EEST) Nexstim Plc (" Nexstim " or " Company ") announces managers' transactions as follows: Person subject to the notification requirement Name: Henri Hannula Position: Other senior manager Issuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 156979/5/4 ____________________________________________ Transaction date: 2026-05-12 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000506811 Nature of transaction: EXERCISE OF A STOCK OPTION (X) Linked to stock option programme Transaction details (1): Volume: 6922 Unit price: 2 EUR (2): Volume: 9791 Unit price: 4.87 EUR (3): Volume: 12311 Unit price: 3.63 EUR Aggregated transactions (3): Volume: 29024 Volume weighted average price: 3.65956 EUR ____________________________________________ Person subject to the notification requirement Name: Henri Hannula Position: Other senior manager Issuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 156985/5/6 ____________________________________________ Transaction date: 2026-05-12 Outside a trading venue Instrument type: DERIVATIVE ISIN: FI4000602834 Nature of transaction: DISPOSAL (X) Made under life insurance policy Transaction details (1): Volume: 6922 Unit price: 5.51 EUR (2): Volume: 9791 Unit price: 2.64 EUR Aggregated transactions (2): Volume: 16713 Volume weighted average price: 3.82866 EUR ____________________________________________ Transaction date: 2026-05-12 Outside a trading venue Instrument type: DERIVATIVE ISIN: FI4000602842 Nature of transaction: DISPOSAL (X) Linked to stock option programme Transaction details (1): Volume: 12311 Unit price: 3.88 EUR Aggregated transactions (1): Volume: 12311 Volume weighted average price: 3.88 EUR Further information is available on the website www.nexstim.com , or by contacting: Mikko Karvinen , CEO +358 50 326 4101 mikko.karvinen @ nexstim . com The Company's Certified Adviser is DNB Carnegie Investment Bank AB. About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. Nexstim's Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb. Nexstim shares are listed on Nasdaq First North Growth Market Finland. For more information, please visit https://www.nexstim.com .